Bauerschlag et al. [62] reported that a continuous application of FASN inhibitor cerulenin combined with cisplatin can prominently reduce the IC50 value to cisplatin in cisplatin-resistant ovarian cancer cells, and that cisplatin-resistant cells show a decreased intake of 18F-fluoromethylcholine (18F-FCH), suggesting that metabolic imaging may be able to guide treatments. Here, FASN is linked to ovarian carcinoma.